Quizartinib

From WikiMD.org
Jump to navigation Jump to search

Quizartinib (pronounced as kwi-zar-ti-nib) is a type of antineoplastic agent specifically classified as a tyrosine kinase inhibitor. It is primarily used in the treatment of acute myeloid leukemia (AML).

Etymology

The name "Quizartinib" is derived from the systematic International Union of Pure and Applied Chemistry (IUPAC) nomenclature. It is a combination of parts of the chemical name "Quinazoline" and "Tyrosine Kinase Inhibitor".

Usage

Quizartinib is used in the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) which is FLT3-ITD positive. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, helping to slow down the growth of these cells.

Related Terms

  • Antineoplastic agent: A substance that inhibits or prevents the proliferation of neoplasms (abnormal growth of tissue).
  • Tyrosine kinase inhibitor: A pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades.
  • Acute myeloid leukemia (AML): A cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood.
  • FLT3: FMS-like tyrosine kinase 3, a protein that, in humans, is encoded by the FLT3 gene. Mutations to this gene are often associated with acute myeloid leukemia.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski